BACKGROUND: The goal of this population-based study was to determine the impact of post-mastectomy radiation therapy on long-term overall survival (OS) of male patients with breast cancer. PATIENTS AND METHODS: We investigated 20-year OS rates of 664 patients diagnosed with primary stage I-III breast cancer in former East Germany between 1970 and 1989. Patients had a radical mastectomy with axillary lymph node dissection without systemic adjuvant therapy. RESULTS: Median follow-up time was 26.2 years (range 19-38 years). 52.4% of the patients had post-mastectomy radiotherapy. Radiotherapy showed different effects in each stage group after 20 years. Whereas there was an OS trend for radiotherapy to harm patients with stage I disease (hazard ratio (HR) 1.45; 95% confidence interval (CI) 0.98-2.15; p = 0.065), radiotherapy showed no benefit in patients with stage II disease (HR 0.82; 95% CI 0.62-1.1; p = 0.15). There was a significant survival benefit for patients with stage III disease receiving radiotherapy (HR 0.60; 95% CI 0.41-0.88; p = 0.008). CONCLUSION: Post-mastectomy radiotherapy is associated with longer OS in male patients with stage III breast cancer. Male breast cancer patients at stages I and II do not seem to benefit from radiotherapy, but obsolete irradiation techniques might explain adverse long-term effects in earlier stages.
BACKGROUND: The goal of this population-based study was to determine the impact of post-mastectomy radiation therapy on long-term overall survival (OS) of male patients with breast cancer. PATIENTS AND METHODS: We investigated 20-year OS rates of 664 patients diagnosed with primary stage I-III breast cancer in former East Germany between 1970 and 1989. Patients had a radical mastectomy with axillary lymph node dissection without systemic adjuvant therapy. RESULTS: Median follow-up time was 26.2 years (range 19-38 years). 52.4% of the patients had post-mastectomy radiotherapy. Radiotherapy showed different effects in each stage group after 20 years. Whereas there was an OS trend for radiotherapy to harm patients with stage I disease (hazard ratio (HR) 1.45; 95% confidence interval (CI) 0.98-2.15; p = 0.065), radiotherapy showed no benefit in patients with stage II disease (HR 0.82; 95% CI 0.62-1.1; p = 0.15). There was a significant survival benefit for patients with stage III disease receiving radiotherapy (HR 0.60; 95% CI 0.41-0.88; p = 0.008). CONCLUSION: Post-mastectomy radiotherapy is associated with longer OS in male patients with stage III breast cancer. Male breast cancerpatients at stages I and II do not seem to benefit from radiotherapy, but obsolete irradiation techniques might explain adverse long-term effects in earlier stages.
Entities:
Keywords:
Adjuvant Therapy; Adjuvant radiotherapy; Male breast cancer; Overall survival
Authors: Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji Journal: J Natl Cancer Inst Date: 2005-01-19 Impact factor: 13.506
Authors: D B Thomas; L M Jimenez; A McTiernan; K Rosenblatt; H Stalsberg; A Stemhagen; W D Thompson; M G Curnen; W Satariano; D F Austin Journal: Am J Epidemiol Date: 1992-04-01 Impact factor: 4.897
Authors: Kaiyumars B Contractor; Kanchan Kaur; Gabriel S Rodrigues; Dhananjay M Kulkarni; Hemant Singhal Journal: World J Surg Oncol Date: 2008-06-16 Impact factor: 2.754
Authors: Frederik Wenz; Elena Sperk; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Christoph Fussl; Rolf Sauer Journal: Strahlenther Onkol Date: 2014-08 Impact factor: 3.621
Authors: Daniel Rolf; Khaled Elsayad; Mohamed A M Meheissen; Yasser Elkerm; Carl Opitz; Isabel Radke; Anne Bremer; Anne Hülskamp; Rasha Elsaka; Horeya M Ismail; Essam Elfaham; Abdelsalam Attia Ismail; Hazem Elmansy; Eva Wardelmann; Amr Abdelaziz Elsaid; Barbara Krause-Bergmann; Joke Tio; Hans Theodor Eich; Oliver Micke Journal: Adv Radiat Oncol Date: 2020-02-20